These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 7639971

  • 1. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H, Arasteh K, Staszewski S, Ruf B, Stellbrink HJ, Schrappe M, Stoehr A, Haase W, Schomaker U, von Eisenhart Rothe B.
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [Abstract] [Full Text] [Related]

  • 2. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
    [Abstract] [Full Text] [Related]

  • 3. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC, Martin ES.
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE.
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [Abstract] [Full Text] [Related]

  • 5. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
    d'Arminio Monforte A, Musicco M, Galli M, Paga C, La Regina A, Lazzarin A, Angarano G, Milazzo F, Gritti F, Arlotti M, Mazzotta F, Visco G, Aiuti F, Moroni M.
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):135-42. PubMed ID: 9105840
    [Abstract] [Full Text] [Related]

  • 6. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
    AIDS; 1996 Jul; 10(8):867-80. PubMed ID: 8828744
    [Abstract] [Full Text] [Related]

  • 7. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP, Liebman HA.
    N Engl J Med; 1990 May 10; 322(19):1340-5. PubMed ID: 2139174
    [Abstract] [Full Text] [Related]

  • 8. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP, Kunches LM, Saunders CA, Perkins CJ, Kelley SL, McLaren C, McCaffrey RP, Liebman HA.
    Rev Infect Dis; 1990 May 10; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [Abstract] [Full Text] [Related]

  • 9. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
    Moyle GJ, Nelson MR, Hawkins D, Gazzard BG.
    Q J Med; 1993 Mar 10; 86(3):155-63. PubMed ID: 8387218
    [Abstract] [Full Text] [Related]

  • 10. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
    Gatell JM, Leal M, Mallolas J, Vidal C, Pumarola T, Parra R, Padró S, Caruz A, Falgueras T, Rey C, Sánchez-Quijano A, Torres Y, Lissen E, Jiménez de Anta MT, Soriano E.
    Antivir Ther; 1996 Apr 10; 1(2):105-12. PubMed ID: 11321180
    [Abstract] [Full Text] [Related]

  • 11. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
    Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD.
    Arch Intern Med; 1995 May 08; 155(9):961-74. PubMed ID: 7726705
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
    Valentine FT, Seidlin M, Hochster H, Laverty M.
    Rev Infect Dis; 1990 May 08; 12 Suppl 5():S534-9. PubMed ID: 1974725
    [Abstract] [Full Text] [Related]

  • 13. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
    Montaner JS, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L.
    J Acquir Immune Defic Syndr (1988); 1994 Sep 08; 7(9):924-30. PubMed ID: 7519674
    [Abstract] [Full Text] [Related]

  • 14. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.
    J Pediatr; 1998 Oct 08; 133(4):500-8. PubMed ID: 9787687
    [Abstract] [Full Text] [Related]

  • 15. Didanosine.
    Shelton MJ, O'Donnell AM, Morse GD.
    Ann Pharmacother; 1992 May 08; 26(5):660-70. PubMed ID: 1350471
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
    Vella S, Floridia M, Dally LG, Tomino C, Fragola V, Weimer LE, Milazzo F, Mazzotta F, Moroni M, Pastore G, Scalise G, Sinicco A, Ortona L, De Rienzo B, Dianzani F.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug 15; 12(5):462-9. PubMed ID: 8757422
    [Abstract] [Full Text] [Related]

  • 17. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L.
    Ann Intern Med; 1994 Mar 01; 120(5):360-8. PubMed ID: 7905722
    [Abstract] [Full Text] [Related]

  • 18. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
    Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G.
    N Engl J Med; 1992 Aug 27; 327(9):581-7. PubMed ID: 1353607
    [Abstract] [Full Text] [Related]

  • 19. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec 01; 19(4):339-49. PubMed ID: 9833742
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
    Floridia M, Vella S, Seeber AC, Tomino C, Fragola V, Weimer LE, Ricciardulli D, Milazzo F, Gritti FM, Mazzotta F, Ranieri S, Chiodo F, Moroni M, Cargnel A, Bassetti D, Giannini V, Cremoni L, Concia E, Sinicco A, Carosi G, Alberici F, Dianzani F.
    J Infect Dis; 1997 Feb 01; 175(2):255-64. PubMed ID: 9203645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.